DC-preT cell therapy

DC-preT cell therapy is an autologous cellular immunotherapy being developed by West China Hospital of Sichuan University for the treatment of advanced non-small cell lung cancer (NSCLC). The therapy utilizes a combination of dendritic cells (DCs) and precursor T cells (preT). Dendritic cells are professional antigen-presenting cells that are used to prime the immune system by presenting tumor-associated antigens to T cells. Precursor T cells are expanded and activated ex vivo before being re-infused into the patient. This combined approach aims to enhance the cellular immune response, specifically targeting and eliminating malignant cells in patients who have failed standard treatment regimens.

Other names

DC-preT cellsDC-preT cellular immunotherapy